Start here if you're new
what it is
Dexcom makes wearable glucose monitors that tell people with diabetes where their blood sugar is, in real time.
how it gets paid
Last year Dexcom made $4.7B in revenue. u.s. cgm systems was the main engine at $2.61B, or 56% of sales.
why it's growing
Revenue grew 15.6% last year. Revenue still grew. Annual sales reached $4.7B, up 15.6%, and preliminary Q4 2025 revenue was $1.26B, up 13% vs. prior year.
what just happened
Dexcom delivered a $0.45 EPS quarter against a $0.72 estimate, and the stock still lives on growth math.
At a glance
B+ balance sheet — decent shape, but not bulletproof
45/100 earnings predictability — expect surprises
35.8x trailing p/e — you're paying up for this one
23.5% return on capital — every dollar works hard here
xvary composite: 63/100 — average
What they do
Dexcom makes wearable glucose monitors that tell people with diabetes where their blood sugar is, in real time.
Dexcom wins because its sensor sits on your body and feeds decisions all day. Switching costs (changing vendors is a hassle) → your doctor, app data, and insulin workflow all need to move → leaving is painful. That grip has helped the business reach a 26.5% operating margin and 23.5% return on capital.
How they make money
$4.7B
annual revenue · their business grew +15.6% last year
u.s. cgm systems
$2.61B
+11.0%
international cgm systems
$1.08B
+18.0%
sensors
$0.66B
+13.0%
receivers and accessories
$0.21B
+8.0%
software and other
$0.14B
+13.0%
The products that matter
real-time diabetes monitoring devices
Continuous Glucose Monitoring Systems
$4.7B revenue · 100% of sales
it's the whole company. all $4.7B in annual revenue comes from CGM, and that business still grew 15.6% last year. focus is the story. concentration is also the story.
100% of revenue
Key numbers
$8.0B
2029 sales
Sales are projected to rise from $4.7B to $8.0B by 2029, about 70% growth. If that path breaks, 35.8x earnings looks rich fast.
26.5%
operating margin
Operating margin → profit after running the business → so what: Dexcom already prints solid earnings while still growing.
23.5%
return on capital
Return on capital → profit from each dollar invested → so what: this is a business that turns spending into cash better than most device makers.
37.5%
earnings surprise
Earnings surprise → how far results missed expectations → so what: one bad quarter can crush a premium stock.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 25 / 100
- long-term debt $1.2B (4% of capital)
- net profit margin 20.8% — keeps 21 cents of every dollar in revenue
- return on equity 26% — $0.26 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in DXCM 3 years ago → it's now worth $6,880.
The index would have given you $14,770.
source: institutional data · total return
What just happened
missed estimates
Dexcom delivered a $0.45 EPS quarter against a $0.72 estimate, and the stock still lives on growth math.
Revenue still grew. Annual sales reached $4.7B, up 15.6%, and preliminary Q4 2025 revenue was $1.26B, up 13% vs. prior year. The problem was expectations, not demand.
$4.7B
revenue
$0.45
eps
59.1%
gross margin
the number that mattered
The -37.5% earnings miss mattered most because premium multiples break when execution wobbles.
-
in mid-january, dexcom reported preliminary fourth-quarter results for 2025.
-
revenues for the december period registered $1.26 billion from an unaudited perspective.
-
this represents a healthy 13% rise from the final quarter of 2024.
-
looking at it with more granularity, domestic receipts were up 11%, to $892 million, while overseas sales chimed in at $368 million, an uptick of 18%.
-
going off these numbers, annual revenues would sum to $4.66 billion, which would have the company set to meet or beat our $2.05 shareearnings estimate when full financial results are released on february 12th.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is pricing or reimbursement pressure in continuous glucose monitoring. when one product category drives all $4.7B of revenue, you do not get to hide from policy or payer changes.
high
CGM reimbursement pressure
Dexcom sells into a medical device category where coverage decisions matter. If payers get tougher on reimbursement, pressure lands on both volume and price.
all $4.7B of revenue sits in CGM. this is not a side risk. it is the business.
med
single-category concentration
The same focus that makes the story easy to understand also makes it fragile. Dexcom does not have another segment to offset a stumble in sensors, adoption, or pricing.
100% of sales come from one category, so any slowdown hits the whole income statement.
med
premium multiple without premium predictability
The stock trades at 35.8x trailing earnings while earnings predictability sits at 45/100. That is a rich setup for a business the market does not fully trust quarter to quarter.
if growth slips below the recent 13–15.6% range, the valuation gets harder to defend fast.
Dexcom is profitable, but concentrated. A hit to CGM pricing, reimbursement, or growth would pressure the 20.0% net margin and leave a 35.8x multiple with less to stand on.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
full Q4 release on february 12
the preliminary print was fine. now you want the full numbers, the margin detail, and management's path from roughly $4.66B to the $5B revenue target.
metric
whether growth holds above the recent range
Q4 revenue grew 13%, while full-year revenue grew 15.6%. if that range weakens, the stock's premium multiple has a problem.
trend
international growth staying ahead of the U.S.
international revenue rose 18% versus 11% in the U.S. that gap matters if domestic growth keeps maturing.
risk
institutional selling pressure easing
433 buyers were outnumbered by 459 sellers last quarter. if that keeps happening, you have to ask who is funding the rerating case.
Analyst rankings
short-term outlook
top 20%
momentum score 2 — in human-speak, analysts still expect above-average stock performance over the next year.
risk profile
average
stability score 3 — this is not a bunker stock, but it is not a disaster setup either.
chart momentum
below average
technical score 4 — the fundamentals and the chart are still telling different stories.
earnings predictability
45 / 100
earnings are harder to model here than the multiple suggests. that mismatch is part of the stock's problem.
source: institutional data
Institutional activity
433 buyers vs. 459 sellers in 3q2025. total institutional holdings: 0.4B shares.
source: institutional data
Price targets
3-5 year target range
$61
$149
$73
current price
$105
target midpoint · +43% from current · 3-5yr high: $180 (+145% · 25% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive